ArticleCirculation research2024
Mitofusin-2 Regulates Platelet Mitochondria and Function.
Open access · greenAbstract read
In one paragraph
Article in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- Mitochondrial quality control in health and disease: Updates 2026.Chinese medical journal · 2026Review
- Platelet Drp1 phosphorylation provides a platform for immune-based platelet function testing.Blood · 2026Article
- Procoagulant platelets: linking coagulation and thromboinflammation in cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Hematopoietic Aging and Leukemia: Mechanistic and Therapeutic Insights.International journal of molecular sciences · 2026Review
- Mesenchymal Stem cell therapy with GHRH receptor analog resolves post-stroke vasogenic edema via modulating AQP4 and mitochondria-ER crosstalk.Journal of translational medicine · 2026Article
- Platelet mTOR Is a Regulator of Sterile Immunothrombosis.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Differential regulation of cyclic adenosine monophosphate by phosphodiesterase 3A discriminates thrombin-induced protease activated receptor 1- and 4-dependent platelet activation.Journal of thrombosis and haemostasis : JTH · 2026Article
- Mitochondrial dysfunction in ARDS: unraveling the regulatory networks and therapeutic opportunities.Frontiers in immunology · 2026Review
- The role of eCyPA as an inflammatory biomarker for predicting 28-day mortality in ARDS patients.Respiratory research · 2025Article
- OAC1 improves mitofusin 2 expression to alleviate neuronal injury following experimental ischemic stroke.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Article
- GPD1L-Mediated Glycerophospholipid Metabolism Dysfunction in Women With Diminished Ovarian Reserve: Insights From Pseudotargeted Metabolomic Analysis of Follicular Fluid.Cell proliferation · 2025Article
- Huayu Qutan formula can improve platelet aggregation in acute coronary syndrome rats by regulating gut microbes to drive trimethylamine/flavin containing monooxygenase 3/trimethylamine N-oxide pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- TNF-α impairs platelet function by inhibiting autophagy and disrupting metabolism via syntaxin 17 downregulation.The Journal of clinical investigation · 2025Article
- Mitochondrial Calcium Uniporter Regulates ITAM-Dependent Platelet Activation.Circulation research · 2025Article
- GPD2 inhibition impairs coagulation function via ROS/NF-κB/P2Y12 pathway.Cellular & molecular biology letters · 2025Article
- Platelets and diseases: signal transduction and advances in targeted therapy.Signal transduction and targeted therapy · 2025Review
- Between endothelial activation and stress index (EASIX) and mortality in acute respiratory distress syndrome (ARDS) patients: a multicenter retrospective study.Frontiers in physiology · 2025Article
- Mitochondrial fusion protein: a new therapeutic target for lung injury diseases.Frontiers in physiology · 2025Review
- Friend or foe: the role of platelets in acute lung injury.Frontiers in immunology · 2025Review
- Effect of Oxidative Stress on Mitochondrial Damage and Repair in Heart Disease and Ischemic Events.International journal of molecular sciences · 2024Review
Corrections and comments
- Commented on by
Authors and funding
28 authors at 8 institutions in 5 countries.
Shancy JacobMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Yasuhiro KosakaMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Seema BhatlekarMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Frederik DenormeMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.ORCID 0000-0003-1442-3568
Haley BenzonMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.ORCID 0000-0003-4994-1269
Alexandra MoodyMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Victoria MoodyMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Emilia A TugolukovaMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Grayson HullMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.ORCID 0009-0001-2069-6987
Nina KishimotoMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Bhanu K ManneMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Li GuoDivision of Hematology and Oncology, Bloodworks Northwest Research Institute, Seattle, WA (L.G.).
Rhonda SouvenirDavid Geffen School of Medicine and UCLA Health (R.S., E.D.A.), Los Angeles, CA.ORCID 0000-0002-8880-2483
Brayden J SeligerMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Alicia S EustesUniversity of Iowa (A.S.E.), Iowa City, IA.ORCID 0000-0001-9436-198X
Kelly HoergerMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Neal D TolleyMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Amir N FatahianDepartment of Nutrition and Integrative Physiology (A.N.F., S. Boudina), University of Utah, Salt Lake City, UT.ORCID 0000-0001-6531-7920
Sihem BoudinaMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.ORCID 0000-0002-4711-1109
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA (D.C.C.).ORCID 0000-0002-0301-0242
Yongyue WeiPeking University Center for Public Health and Epidemic Preparedness and Response, Beijing, China (Y.W.).ORCID 0000-0002-1132-1796
Can JuDepartment of Biostatistics, School of Public Health, Nanjing Medical University, Jiangsu, China (C.J.).
Robert A CampbellMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.ORCID 0000-0003-0027-694X
Matthew T RondinaMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
E Dale AbelDavid Geffen School of Medicine and UCLA Health (R.S., E.D.A.), Los Angeles, CA.ORCID 0000-0001-5290-0738
Paul F BrayMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.ORCID 0000-0002-8672-3183
Andrew S WeyrichMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.
Jesse W RowleyMolecular Medicine Program, (S.J., Y.K., S. Bhatlekar, F.D., H.B., A.M., V.M., E.T., G.H., N.K., B.K.M., B.J.S., K.H., N.D.T., S. Boudina, R.A.C., M.T.R., P.F.B., A.S.W., J.W.R.), University of Utah, Salt Lake City, UT.ORCID 0000-0003-4444-1724
University of Utah · USUniversity of California, Los Angeles · USBloodworks Northwest · USHarvard University · USNanjing Medical University · CNOklahoma Medical Research Foundation · USPeking University · CNUniversity of Iowa · US
Funding
Translational Research Skills Development CoreU54HL112311 · NHLBI · UNIVERSITY OF UTAH · PI WEYRICH, ANDREW S, ZIMMERMAN, GUY A. · 2012 to 2016
$12.9MTranslational Control of Megakaryocyte and Platelet Gene Expression in DiseaseR35HL145237 · NHLBI · UNIVERSITY OF UTAH · PI WEYRICH, ANDREW S · 2019 to 2025
$4.7MGenetic risks for ALI in ARDSnet and the iSPAAR ConsortiumRC2HL101779 · NHLBI · UNIVERSITY OF WASHINGTON · PI WURFEL, MARK M · 2009 to 2010
$4.7MMitochondrial fusion protein MFN2 prevents platelet death and dysfunctionR01HL144957 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI JESSE ROWLEY · 2019 to 2026
$3.2MTranslational Control of Megakaryocyte and Platelet Function in SepsisR01HL142804 · NHLBI · UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2018 to 2021
$1.9MThe Platelet Metabolome in ObesityK01GM103806 · NIGMS · UNIVERSITY OF UTAH · PI ROWLEY, JESSE · 2012 to 2016
$802kPlatelet-Leukocyte Interactions in SepsisK24HL155856 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RONDINA, MATTHEW THOMAS · 2021 to 2025
$606kPlatelet Reprogramming During InflammationI01CX001696 · VA · VA SALT LAKE CITY HEALTHCARE SYSTEM · PI Matthew Thomas Rondina · 2018 to 2026
–CSRD VA I01 CX001696NHLBI NIH HHS K24 HL155856NHLBI NIH HHS R01 HL142804NHLBI NIH HHS R01 HL144957NHLBI NIH HHS R35 HL145237NHLBI NIH HHS RC2 HL101779NHLBI NIH HHS U54 HL112311NIGMS NIH HHS K01 GM103806
Abstract
backgroundSingle-nucleotide polymorphisms linked with the rs1474868 T allele (
methodsMice with megakaryocyte/platelet deletion of
resultsMitochondria was more fragmented in megakaryocytes derived from
conclusionsMfn2 preserves mitochondrial phenotypes in megakaryocytes and platelets and influences platelet life span, function, and outcomes of stroke and lung injury.
Indexed as
Acute Lung InjuryLipopolysaccharidesAgedAnimalsBlood PlateletsGTP PhosphohydrolasesHemorrhageHumansMiceMitochondriaPhosphatidylserinesGTP PhosphohydrolasesLipopolysaccharidesMfn2 protein, mousePhosphatidylserinesblood plateletsischemic strokemegakaryocytesmitochondrianeutrophils
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.